April 2014
Volume 55, Issue 13
ARVO Annual Meeting Abstract  |   April 2014
New handheld, non-mydriatic ERG device to screen for diabetic retinopathy and other eye diseases
Author Affiliations & Notes
  • Byongdo Kim
    University of California, Berkeley, Berkeley, CA
  • Evelyn Ross
    University of Iowa College of Public Health, Iowa City, CA
  • Kimberly Pham
    University of California, Berkeley, Berkeley, CA
  • Jenny Nguyen
    University of Southern California, Los Angeles, CA
  • Vinna Nam
    University of California, Berkeley, Berkeley, CA
  • Vidhya Gunasekaran
    Ophthalmology, Aravind Eye Hospital, Madurai, India
  • Scott E Brodie
    Ophthalmology, Mount Sinai School of Medicine, New York City, NY
  • Gloria Wu
    Ophthalmology, Stanford Hospital & Clinics, Stanford, CA
  • Footnotes
    Commercial Relationships Byongdo Kim, None; Evelyn Ross, None; Kimberly Pham, None; Jenny Nguyen, None; Vinna Nam, None; Vidhya Gunasekaran, None; Scott Brodie, None; Gloria Wu, None
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science April 2014, Vol.55, 5118. doi:https://doi.org/
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Byongdo Kim, Evelyn Ross, Kimberly Pham, Jenny Nguyen, Vinna Nam, Vidhya Gunasekaran, Scott E Brodie, Gloria Wu, VN; New handheld, non-mydriatic ERG device to screen for diabetic retinopathy and other eye diseases. Invest. Ophthalmol. Vis. Sci. 2014;55(13):5118. doi: https://doi.org/.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

To evaluate the use of the 30 Hz RETeval(TM) handheld ERG device in diabetic and glaucoma patients in the office setting.


The RETeval(TM) (LKC Gaithersburg, MD) is a small handheld ERG device using adhesive skin electrodes in lieu of contact lens electrodes to assess cone function in patients without mydriasis. The RETeval(TM) is currently in Phase 2 and 3 clinical trials (US FDA, and EC, respectively). RETeval(TM) (REv) was used in patients with diabetes mellitus and glaucoma patients in a retina practice in San Jose, CA. Inclusion criteria: Diabetic pts HbA1c > 6.0 mg/dL or FBS > 100 mg/dL; Glaucoma patients were verified by visual field findings. Visual acuity was 20/15-20/40. The Stata statistical software program was used. For each patient, ERG data from only one eye was used, based on randomization by coin toss. Informed consent was obtained.


A total of 50 patients and controls were enrolled over 3 months: Control (C): n=22: age range 23-75 yrs, avg=47.9, sd=16.3; Diab (DM): n=12: age range 23-77 yrs, avg=55.8,sd=14.6; Glaucoma (G) n=17: age range=37-76 yrs, avg=59.2, sd=11.95. ERG photopic implicit times were prolonged in both diabetic and glaucoma patients: 2 tailed t-test: Control mean 33.2 msec vs DM mean 34.6 msec, implicit time p=0.045; Control mean 33.2 msec vs G mean 35.4 msec, implicit time p=0.0009. No significant differences were noted between implicit times in the diabetic and glaucomatous patients or for difference in response in amplitude: C vs DM: p=0.26.


This small study suggests that prolongation of flicker implicit times in diabetes and glaucoma can be discerned with the RETeval(TM) in a clinical setting. The RETeval(TM) may thus be of value as a screening tool in nursing homes or facilities where ophthalmic exams are not available.

Keywords: 498 diabetes • 509 electroretinography: clinical • 465 clinical (human) or epidemiologic studies: systems/equipment/techniques  

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.